Publishing options:
CRUI institution associated corresponding authors

Key information

1. How do we determine eligibility of the article for the CRUI agreement?

- The acceptance date of the article should be on or after the start date of the agreement
- The corresponding author must be affiliated with a participating institution in the agreement
- The article must be from a participating journal
- The article must be associated with the eligible article type

Key information

2. What is the definition of the corresponding author for the purpose of the agreement?

- Corresponding author is the author who submits the article to Elsevier and stays in contact with Elsevier in the end-to-end journey
- This is the author who makes the publishing choice on behalf of the author group
- Every article has one corresponding author

Key information

3. **Role of the institutional Librarian/Admin in the Elsevier OA Platform (EOAP)**

- By the time the article is in your EOAP, we have published the first version of the article in ScienceDirect (within 48 hours of acceptance)

- You therefore do not approve the publication of the article; you validate whether the corresponding author can make use of the APC funding under the agreement

Retrospective campaign for eligible articles pre-implementation

Retrospective activity category	Next Steps	Actions (after implementation of the agreement for authors)
Gold OA in Hybrid journals	• **Elsevier**: Will share the list of articles with CRUI in an excel spreadsheet. • **CRUI**: Provide confirmation whether the article is eligible for the agreement. Inform institutions about the process and timelines. • **Elsevier**: Upon manual approval from CRUI, Elsevier will credit the invoice and refund if necessary. The request will then appear in EOAP for validation. • **Institution**: Provide approval in EOAP by validating the APC request. Upon approval, the amount will be drawn from the prepaid amount	STMJ implementation team will work with Researcher Support to arrange the credits, refunds and reopening the journeys once we have a confirmation from the institutions.
Gold OA in fully gold	• **Elsevier**: Will share the list of articles with CRUI in an excel spreadsheet. • **CRUI**: Provide confirmation whether the article is eligible for the agreement. Inform institutions about the process and timelines. • **Elsevier**: Upon manual approval from CRUI, Elsevier will credit the invoice and refund if necessary. The request will then appear in EOAP for validation. • **Institution**: Provide approval in EOAP by validating the APC request. Upon approval, the amount will be drawn from the prepaid amount	STMJ implementation team will work with RS to arrange the credits, refunds and reopening the journeys once we have a confirmation from the institutions.
Subscription in Hybrid journals	• **Elsevier**: Will share the list of articles that have been published in subscription on eligible journals, with CRUI in an excel spreadsheet • **CRUI**: Contact institutions and provide a heads up about the below process • **Elsevier**: Will contact the institutions copying CRUI providing the email template, and list of the activation links along with the corresponding author's names. • **Institutions**: Contact the authors, using the template provided (Insert the relevant author's name and the activation links from the file) and follow up in case of no response • **Institutions**: Check the EOAP/Reports to view whether the author has opted for OA	STMJ implementation will share the reports and details needed by the institutions to contact the authors.

Publishing options after acceptance

Finalize Publishing your Article

[redacted]

Corresponding author	[redacted]
E-mail address	[redacted]
Journal	International Journal of Pharmaceutics
Article number	121624
Our reference	IJP_121624
PII	S0378-5173(22)00179-X

Corresponding author receives an email post acceptance with a unique link to complete the author journey and choose publishing options

Author clicks on Complete the Rights and Access information form

Welcome [redacted]

To help us finalize the publication of your article please complete the publishing form(s) below.

Note: you will receive a confirmation e-mail after completing each form.

Information you may need to provide to complete the forms

Rights and Access

Complete the rights and access form >

Help and Support

How you can share your article

Author rights information

A guide to publishing Open Access

Feedback

Rights and Access

1 Corresponding Author — 2 Co-Author — 3 Research Funders — 4 Publishing Options — 5 Review Order — 6 Confirmation

Corresponding author selects his/her affiliation details which we use to identify the authors and match them to the CRUI agreement

Please note that the author has already provided this information at submission; it is prepopulated

[redacted]

Corresponding author [redacted]
E-mail address [redacted]
Journal [redacted]
Article number [redacted]
Our reference [redacted]
PII [redacted]

Corresponding Author's Organization

Please enter the corresponding author's organization. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

Hint: start your search using your main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find your specific department, then selecting your main organization is sufficient. For more tips on searching for an organization please visit our Support Center.

Organization name*

University of Milan

University of Milan
Milano, IT
University of Milan Library of Biology
Milano, IT
University of Milan Library of Computer Science
Milano, IT
University of Milano–Bicocca University Library
Milano, IT
University of Milano–Bicocca
Milano, IT

Save and Continue >

Copyright © 20 [redacted] nditions Privacy Policy Cookie Notice Contact us

Rights and Access

1 Corresponding Author — 2 Co-Author — 3 Research Funders — 4 Publishing Options — 5 Rights — 6 Publishing Agreement — 7 Review Order — 8 Confirmation

Were there any co-authors for this article?

- (•) Yes
- ( ) No

Corresponding author also adds the co-author affiliation details

Add Co-author Details

Please provide details for all co-authors. We use this information so we can offer tailored publishing options and a personalized article publishing charge for Gold open access when applicable.

Hint: start the organization search using the main organization name (e.g. University of Manchester) as this will return the most results from which to select the most appropriate option. If you're unable to find the specific department, then selecting the main organization is sufficient. For more tips on searching for an organization please visit our Support Center.

First name or initial* John

Last name* Head

Organization name* KU Leuven

Or use recently selected organization

+ Add another co-author

Previous

Save and Continue >

Rights and Access

1 Corresponding Author — 2 Co-Author — 3 Research Funders — 4 Publishing Options — 5 Rights — 6 Publishing Agreement — 7 Review Order — 8 Confirmation

[blurred]

Did the research in this article receive funding?

- (•) Yes
- ( ) No

Author can add the Funder details. Funder can be the affiliated institution or a different one. In this case it is Milliman

Funder Details

Determine the best publishing options for your article. Please include the details about any funding received outside of your primary affiliations. If providing details for two or more organizations, please list the organization(s) that provided the most funding first.

For tips on searching for an organization please visit our Support Center

Organization name*
Milliman Inc

Grant/Contract numbers*
GT123

+ Add grant/contract number

+ Add another organization

Previous

Save and Continue >

Feedback

- In hybrid journals, the author sees the Publishing Options based on the affiliation details provided. Gold OA option is followed by Subscription option, and we inform the author that agreement covers the APC
- If the librarian/admin at the institution rejects the author request in the Elsevier Platform, we also make it clear that the authors will receive a full price invoice
- Author selects Gold OA



- **In case of Gold OA journals, author sees only the Gold OA publishing option and we inform the author that institution covers the APC**
- **If the librarian/admin at the institution rejects the author request in the Elsevier Platform, we also make it clear that the authors will receive a full price invoice**



Rights and Access

1 Corresponding Author — 2 Co-Author — 3 Research Funders — 4 Publishing Options — 5 Licenses — 6 Rights — 7 Publishing Agreement — 8 Review Order — 9 Confirmation

- **System presents the author with the CC license options**
- **CC BY option is pre-selected**

Select your user license

Please select your license. If you need to comply with a mandated license and the mandated license is not listed below, please visit our Support Hub for additional help.

(•) **CC BY 4.0**

A license to permit readers to share and adapt your article for any purpose, even commercially.

Read more about CC BY 4.0

( ) **CC BY-NC-ND 4.0**

A license to permit readers to share all or part of your article in any medium or format for non-commercial purposes. Permission from Elsevier is required for the distribution of derivative versions of the article or for commercial use.

Read more about CC BY-NC-ND 4.0

Previous Save and Continue >

Copyright © 2023 Elsevier, except certain content provided by third parties. Terms & Conditions Privacy Policy Cookie Notice Contact us

Cookies are set by this site. To decline them or learn more, visit our Cookie Settings

RELX Group™

1 Corresponding Author — 2 Co-Author — 3 Research Funders — 4 Publishing Options — 5 Licenses — 6 Rights — 7 Publishing Agreement — 8 Review Order — 9 Confirmation

[redacted]

Elsevier B.V.

Select Your Status

- ○ **I am the sole author of the manuscript**
- ◉ **I am one author signing on behalf of all co-authors of the manuscript**

  Please indicate which of the below applies to you:

  - ○ We are all US Government employees and the Article is public domain and therefore the 'License of publishing rights' clause does not apply
  - ○ I am a US Government employee but some of my co-authors are not
  - ○ I am not a US Government employee but some of my co-authors are
  - ○ The work was performed by contractors of the US Government under contract number:

    Contract Number*

  - ○ All or some of the authors are UK, Canadian or Australian Government employees and Crown Copyright is asserted
  - ○ Some of the authors are employees of the UK, Canadian or Australian Government but Crown Copyright is not asserted
  - ◉ None of the above
- ○ **I am signing as an authorized representative and on behalf of my employer**

Author selects the rights

Signed on Behalf of Corresponding Author

Please complete this section if you are not the corresponding author as listed above. A copy of the agreement will be sent to you and the corresponding author.

☐ **I am signing on behalf of the corresponding author**

Name, job title and company (if employer representative)*

E-mail address*

Previous

Save and Continue ›

Rights and Access

1 Corresponding Author — 2 Co-Author — 3 Research Funders — 4 Publishing Options — 5 Licenses — 6 Rights — 7 Publishing Agreement — 8 Review Order — 9 Confirmation

[redacted]

Elsevier B.V.

Your Status

- I am one author signing on behalf of all co-authors of the manuscript

System presents author with the Journal License Publishing Agreement

License of Publishing Rights

I hereby grant to Elsevier B.V. an exclusive publishing and distribution license in the manuscript identified above and any tables, illustrations or other material submitted for publication as part of the manuscript (the "Article") in print, electronic and all other media (whether now known or later developed), in any form, in all languages, throughout the world, for the full term of copyright, and the right to license others to do the same, effective when the Article is accepted for publication. This license includes the right to enforce the rights granted hereunder against third parties.

Supplemental Materials

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

With respect to any Supplemental Materials that I submit, Elsevier B.V. shall have a perpetual worldwide non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials, in all forms and media (whether now known or later developed) and permit others to do so. The publisher shall apply the same end user license to the Supplemental Materials as to the Article where it publishes the Supplemental Materials with the Article in the journal on its online platforms on an Open Access basis.

Research Data

"Research Data" shall mean the result of observations or experimentation that validate research findings and that are published separate to the Article, which can include but are not limited to raw data, processed data, software, algorithms, protocols, and methods.

Author agrees to the Journal License Publishing Agreement

For further information see the publishing ethics page at https://www.elsevier.com/about/our-business/policies/publishing-ethics and the journal home page. For further information on sanctions, see https://www.elsevier.com/about/our-business/policies/trade-sanctions

Author representations

- The Article I have submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article and the Supplemental Materials do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libellous or other unlawful matter.
- I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in the Article or the Supplemental Materials.
- Except as expressly set out in this License Agreement, the Article is not subject to any prior rights or licenses.
- If I and/or any of my co-authors reside in Iran, Cuba, or Syria, the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If I am using any personal details or images of patients, research subjects or other individuals, I have obtained all consents required by applicable law and complied with the publisher's policies relating to the use of such images or personal information. See https://www.elsevier.com/about/our-business/policies/patient-consent for further information.
- Any software contained in the Supplemental Materials is free from viruses, contaminants or worms.
- If the Article or any of the Supplemental Materials were prepared jointly with other authors, I have informed the co-author(s) of the terms of this License Agreement and that I am signing on their behalf as their agent, and I am authorized to do so.

Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state of International Federation of Automatic Control ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

For information on the publisher's copyright and access policies, please see http://www.elsevier.com/copyright.

☑ **I have read and agree to the terms of the License Agreement.**

17 December 2021 T-copyright license-v5/2017

Previous Accept Agreement >



Once the author clicks on 'Finish':

- **Corresponding author and coauthors receive a copy of summary via email**
- **Article becomes OA on ScienceDirect within 24 hours**
- **Librarian/admin at the institution will receive a notification for validation within 48 hours who then has 3 weeks to validate the request**
- **If the Librarian/admin approves the request, the author will receive the full APC coverage**
- **If the Librarian/admin rejects the request, the author will receive the full price invoice**

In case Gold OA journal, the author will see the following text.

"If your institution cannot confirm your affiliation, you will receive a full price invoice for USD 4,050 (ex VAT)."

Retrospectively switching subscription articles to OA post implementation

CRUI has access to Live reports in EOAP where they can view the list of subscription articles activated under the agreement. The reports will have author name and email addresses. As per the process CRUI can contact the author to switch their articles to OA if OA is the author preferred option. Below shows the e-mail templates CRUI and the authors can use to change their option to OA.

Dear Author,

I am contacting you with regards to your article [DOI] published with Elsevier.

I understand that you are affiliated with '[institution name]' and you are eligible to publish open access (OA) free of charge under the CRUI agreement. I see that you have chosen to publish under the subscription model. If you are happy to publish OA, please contact oasupport@elsevier.com to retrospectively change your publishing option to OA using the email template below.

Support email address: oasupport@elsevier.com
Subject: [Open Access]: Requesting OA retrospectively

Dear Support,

[DOI number]

I would like to change my publishing option to OA for this article. Would you please guide me on the next steps?

Support for authors and librarians/admins

- Author queries – support@elsevier.com
- Librarian/Admin queries, EOAP account set up or changes – agreementactivation@elsevier.com
- Author journey videos: https://service.elsevier.com/app/answers/detail/a_id/29789/supporthub/publishing/track/APN2ZgoIDv8a~RNiGvwa~yKgpv0qOS75Mv9e~zj~PP_X/

ELSEVIER

Thank you